Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
With
Oregon Health and Science University
Johns Hopkins University
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
The subject must be ≥ 18 years old on the day of consent.
The subject is able to understand written and spoken English.
The patient must have histologically or cytologically confirmed prostate adenocarcinoma.
The subject must have castration-resistant prostate cancer (CRPC).
The subject must have metastatic disease involving bone, seen on radiographic imaging (bone scan, CT scan, PET scan, or MRI).
The subject must be in a castrate state (e.g., currently receiving androgen deprivation therapy or have had an orchiectomy).
The subject must be starting any line of systemic treatment post-androgen deprivation/antiandrogen therapy, with any of the following: chemotherapy (e.g., docetaxel, paclitaxel, carboplatin, cabazitaxel, or mitoxantrone); abiraterone acetate; MDV3100; ketoconazole; a clinical trial.
The subject owns or has regular access to a telephone (cellular or land line).
The subject is willing and able to self-report pain and analgesic use via an automated telephone system.
The subject is willing and able to provide informed consent.
You may not be if
The subject has small cell or predominantly neuroendocrine differentiated prostate tumor.
Clareo Health | Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
